The Human Cdc14 Phosphatases Interact with and Dephosphorylate the Tumor Suppressor Protein p53*

The yeast Cdc14 phosphatase has been shown to play an important role in cell cycle regulation by dephosphorylating proteins phosphorylated by the cyclin-dependent kinase Cdc28/clb. We recently cloned two human orthologs of the yeastCDC14, termed hCDC14A and -B, the gene products of which share ∼80% amino acid sequence identity within their N termini and phosphatase domains. Here we report that the hCdc14A and hCdc14B proteins interact with the tumor suppressor protein p53 both in vitro and in vivo. This interaction is dependent on the N termini of the hCdc14 proteins and the C terminus of p53. Furthermore, the hCdc14 phosphatases were found to dephosphorylate p53 specifically at the p34Cdc2/clb phosphorylation site (p53-phosphor-Ser315). Our findings that hCdc14 is a cyclin-dependent kinase substrate phosphatase suggest that it may play a role in cell cycle control in human cells. Furthermore, the identification of p53 as a substrate for hCdc14 indicates that hCdc14 may regulate the function of p53.

The yeast Cdc14 phosphatase has been shown to play an important role in cell cycle regulation by dephosphorylating proteins phosphorylated by the cyclin-dependent kinase Cdc28/clb. We recently cloned two human orthologs of the yeast CDC14, termed hCDC14A and -B, the gene products of which share ϳ80% amino acid sequence identity within their N termini and phosphatase domains. Here we report that the hCdc14A and hCdc14B proteins interact with the tumor suppressor protein p53 both in vitro and in vivo. This interaction is dependent on the N termini of the hCdc14 proteins and the C terminus of p53. Furthermore, the hCdc14 phosphatases were found to dephosphorylate p53 specifically at the p34 Cdc2 /clb phosphorylation site (p53-phosphor-Ser 315 ). Our findings that hCdc14 is a cyclin-dependent kinase substrate phosphatase suggest that it may play a role in cell cycle control in human cells. Furthermore, the identification of p53 as a substrate for hCdc14 indicates that hCdc14 may regulate the function of p53.
Cdc14 is a protein phosphatase conserved from yeast to man (1). Genetic analyses suggest that the yeast Cdc14 plays pleiotropic roles during the cell cycle, including the regulation of DNA replication and the exit from mitosis (2,3). Recent studies indicate that Cdc14 can, in at least two ways, antagonize the cyclin-dependent kinase Cdc28/clb, which is the master regulator of the cell cycle in yeast (5). Firstly, Cdc14 dephosphorylates the substrates phosphorylated by Cdc28/clb (4). Secondly, Cdc14 dephosphorylates the transcription factor Swi5, resulting in the nuclear accumulation of Swi5 and the transactivation of the Cdc28/clb inhibitor Sic1 (6). The Cdc14 is itself regulated by compartmentalization in the nucleus. During the G 1 , S, G 2 , and early mitosis Cdc14 is anchored in the nucleolus and redistributed throughout the nucleus at the beginning of anaphase (7,8).
Our laboratory has cloned two human orthologs of the yeast CDC14, termed hCDC14A and hCDC14B, the gene products of which share ϳ80% amino acid sequence identity within their N termini and phosphatase domains (1). Both hCdc14A and hCdc14B were found to be localized to the nucleus when overexpressed in mammalian cells. Using the yeast strain harboring a temperature-sensitive mutation in the CDC14 gene, we showed that introduction of either of the two human CDC14 genes could suppress the phenotype of the yeast cdc14 temper-ature-sensitive mutant. This finding suggests that the hCdc14s may perform functions in human cells similar to those performed by the Cdc14 in yeast.
Analogous to the inactivation of the yeast Cdc28/clb by Swi5induced Sic1, the human p34 Cdc2 /clb kinase can in part be inactivated by the p53-regulated Cdk inhibitor p21 WAF1 (9). Interestingly, p53 can be phosphorylated by human p34 Cdc2 /clb at serine 315 (10), parallel to the fact that Swi5 is phosphorylated by the yeast Cdc28/clb kinase (11). Because the yeast Cdc14 can dephosphorylate Swi5, we wanted to explore whether the hCdc14A and hCdc14B may dephosphorylate p53.
In this study, we report that the two hCdc14 phosphatases physically interact with the p53 protein both in vitro and in vivo. Such interaction involves the highly conserved N termini of the hCdc14 proteins and the C terminus of p53. Furthermore, both hCdc14 forms could specifically dephosphorylate the p34 Cdc2 /clb phosphorylation site of p53 (Ser 315 ). We propose that hCdc14 phosphatases may, together with p34 Cdc2 , regulate p53 function by controlling the phosphorylation status of Ser 315 of p53.

MATERIALS AND METHODS
Yeast Strains, Plasmids, and Recombinant Proteins-The Saccharomyces cerevisiae EGY48 strain was obtained from CLONTECH and cultured according to the manufacturer's suggested condition (CLON-TECH). To generate the pLexA-hCdc14B plasmid, the hCdc14B open reading frame (ORF) 1 was cloned in-frame into the BamHI/XhoI restriction sites of the pLexA vector (CLONTECH). The pLexA-PTP3 plasmid was constructed by ligating the PCR product of the S. cerevisiae phosphatase PTP3 ORF in-frame into the EcoRI/XhoI restriction sites of the pLexA vector. The pB42AD-p53 plasmid was constructed by ligating the PCR product of the human p53 ORF in-frame into the EcoRI/XhoI restriction sites of the pB42AD vector (CLONTECH). The construction of the green fluorescent protein fusion plasmids pEGFP-hCdc14A, pEGFP-hCdc14As, and pEGFP-hCdc14B, as well as the plasmids pT7H-Cdc14A, pT7H-Cdc14B, pET-Cdc14A, and pET-Cdc14B were accomplished as described previously (1).
To make the pET-Cdc14A 1-158 and pET-Cdc14A 120 -580 plasmids, the hCdc14A coding sequences from nucleotide 1 to 474 and 360 to 1740, respectively, were PCR-amplified and ligated in-frame into the NdeI/ XhoI restriction sites of the pET23a vector (Novagen). The plasmids pET-Cdc14B 1-230 and pET-Cdc14B 150 -459 were constructed by PCR amplifying the coding sequence of hCdc14B from nucleotide 1 to 690 and 450 to 1377, respectively, followed by ligation in-frame into the NdeI/ XhoI restriction sites of the pET23a vector.
The GST-p53 fusion plasmid pGST-p53 was constructed by cloning human p53 ORF in-frame into the EcoRI/XhoI restriction sites of the pGEX-5X-1 vector (Amersham Pharmacia Biotech). To make pGST-p53 1-210 , pGST-p53 100 -296 , and pGST-p53 250 -393 , the coding sequence of human p53 from nucleotides 1 to 630, 300 to 788, and 750 to 1179, respectively, were PCR-amplified and ligated in-frame into the EcoRI/ * This work was supported by Cancer Biology Training Program National Institutes of Health Grant CA09676 (to L. L.) and by the Walther Cancer Institute (to J. E. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
XhoI restriction sites of the pGEX-5X-1 vector. All constructs were sequenced using automated sequencing (University of Michigan Sequencing Core Facility).
To synthesize 35 S-labeled hCdc14 proteins, an in vitro transcription/ translation system from Promega was used. Recombinant His 6 -tagged hCdc14 and GST-p53 proteins were prepared from Escherichia coli as described previously (1,12).
Two-hybrid Analysis-The yeast strain EGY48 was transformed with the bait plasmids pLexA, pLexA-hCdc14B, or pLexA-PTP3 as described previously (1). Transformants carrying the bait plasmids were selected on SD ϪUra, ϪHis plates. EGY48 cells carrying bait plasmids were then transformed with the prey plasmids pB42AD or pB42AD-p53, and the transformants were selected on SD ϪUra, ϪHis, ϪTrp plates. Any interactions between the expressed protein products from the bait and prey constructs result in the activation of the reporter genes LEU and lacZ enabling the yeast cells to grow on SD ϪUra, ϪHis, ϪTrp, ϪLeu (SD-UHWL) plates. X-gal was included in the growth agar in order for the colonies expressing lacZ to turn blue.
In Vivo Expression of hCdc14 and Immunoprecipitation-The Epstein-Barr virus-transformed human cell line 293 was maintained in Dulbecco's modified Eagle's medium with 10% fetal bovine serum and 10 units/ml penicillin/streptomycin. Cells were transfected with the plasmids pEGFP-hCdc14A, pEGFP-hCdc14As, or pEGFP-hCdc14B using LipofectAMINE according to the manufacturer's instructions (Life Technologies, Inc.). 48 h after transfection, cells were lysed in a phosphate-buffered saline buffer containing 1% Triton X-100, 50 mM NaCl, 1 mM dithiothreitol, proteinase inhibitor mix (BMB). Endogenous p53 was immunoprecipitated using polyclonal anti-p53 antibody (BMB). The immunoprecipitates were washed with lysis buffer five times and subjected to SDS-PAGE analysis. The gel was blotted onto polyvinylidene difluoride membrane and probed with anti-EGFP monoclonal antibody (CLONTECH) to analyze whether any EGFP-hCdc14 fusion proteins may co-immunoprecipitate with p53.
In Vitro Binding Assay-In vitro translated and 35 S-labeled hCdc14 proteins were incubated with glutathione-agarose-immobilized GST-p53 fusion proteins at 4°C for 2 h in PBST (4 mM NaH 2 PO 4 , 16 mM Na 2 HPO 4 , 100 mM NaCl, 0.5% Triton X-100, pH 7.4), 0.05% ␤-mercaptoethanol, 10% glycerol, and 0.2 mM phenylmethylsulfonyl fluoride. After washing the agarose beads six times with the above buffer, SDS sample buffer was added, and the samples were boiled for 5 min and analyzed using SDS-PAGE. The gel was treated with Amplify (Amersham Pharmacia Biotech) and exposed to x-ray film.
In Vitro Dephosphorylation of p53-Purified recombinant GST-p53 fusion proteins were phosphorylated in vitro by either p34 Cdc2 /cyclin B kinase or CKII according to the conditions provided by the manufacturer (New England Biolabs). The phosphorylated GST-p53 fusion proteins (300 ng) in 50 l of glutathione-agarose beads were mixed with 1 g of recombinant hCdc14A, hCdc14B, PTEN, YG4E, or bovine serum albumin in 20 mM Tris-HCl, pH 7.5, 100 mM NaCl, 1 mM dithiothreitol at 30°C for 30 min. GST-p53 protein-agarose beads were then precipitated by centrifugation. The relative amounts of 32 P released into the supernatant as well as the 32 P bound to p53 were quantitated by scintillation counting.

Human Cdc14
Proteins Interact with p53 in Vivo-To study whether the hCdc14 proteins could interact with the p53 protein, we used the yeast two-hybrid assay. After co-transformation of pLexA-hCdc14B and pB42AD-p53 plasmid into the S. cerevisiae EGY48 strain, the LEU reporter gene within the EGY48 strain was activated and enabled the yeast cell to grow on selective media (see "Materials and Methods" for details). The colonies turned blue as a result of lacZ gene activation (Fig. 1A). Yeast cells transformed with either pLexA-hCdc14B or pB42AD-p53 alone could not grow on the selective medium. Co-transformation with another unrelated phosphatase, yeast PTP3 in the pLexA vector (pLexA-PTP3), along with pB42AD-p53 did not result in the activation of the reporter gene (Fig.  1A). These results indicate that the hCdc14B protein can physically interact with p53.
To determine whether hCdc14A and hCdc14B interact with p53 in mammalian cells, we performed co-immunoprecipitation experiments using extracts from 293 cells transfected with either the EGFP-Cdc14A or EGFP-Cdc14B fusion construct (pEGFP-Cdc14A and pEGFP-Cdc14B). Immunoprecipitation of p53 was performed 48 h after transfection using anti-p53 antibodies. The immunoprecipitates were subjected to SDS-PAGE and Western blot analysis with anti-EGFP antibodies. As shown in lane 1 of Fig. 1B, a band corresponding in size to the EGFP-hCdc14A fusion protein (93 kDa) was detected on the blot, suggesting that EGFP-hCdc14A and p53 proteins co-existed in the immunocomplex. Lane 3 shows a band corresponding in size to the EGFP-hCdc14B fusion protein (82 kDa), suggesting that the hCdc14B protein also formed immunocomplexes with the p53 protein. Interestingly, p53 could also form immunocomplexes with EGFP-hCdc14As, which lacks the Cterminal domain (truncated from amino acid 365). This result suggests that hCdc14s interact with p53 via their highly conserved N-terminal domain.
To ensure that the interaction between the hCdc14 phosphatases and p53 was specific and unique, the 293 cells were transfected with either the EGFP vector alone or with another EGFP fusion construct coding for a putative dual specific protein phosphatase PTEN (pEGFP-PTEN). In these experiments, we could not detect any co-immunoprecipitation of either PTEN or EGFP with the anti-p53 antibody (expected size of 75 and 27 kDa, respectively) (lanes 4 and 5). Western blot with whole cell lysates indicated that all EGFP fusion proteins were expressed at similar levels (data not shown). Taken together, the results obtained with both the yeast two-hybrid system and FIG. 1. Human Cdc14 proteins interact with p53. A, two-hybrid analysis of the interaction between hCdc14B and p53. Plasmids were transformed into S. cerevisiae EGY48 strain as described under "Materials and Methods." Transformants carrying different combinations of plasmids were plated onto SD ϪUra, ϪHis, ϪTrp, ϪLeu, ϩX-gal plate. Only the strain carrying pLexA-hCdc14B and pB42AD-p53 plasmids can grow and turn blue on such a plate. B, co-immunoprecipitation of p53 and human GFP-Cdc14 fusion proteins. 293 cells were transfected with pEGFP-hCdc14A, pEGFP-hCdc14As, pEGFP-hCdc14B, pEGFP-PTEN, or pEGFP-C2 (lanes 1-5) as described under "Materials and Methods." Following immunoprecipitation with polyclonal anti-p53 antibody, the immunoprecipitated proteins were analyzed on SDS-PAGE and blotted with monoclonal anti-EGFP antibody. The expected positions of human EGFP-hCdc14A, EGFP-hCdc14As, and EGFP-hCdc14B are marked.
with the immunoprecipitation experiments demonstrated that the hCdc14A and hCdc14B phosphatases can physically interact with p53.
The N terminus of hCdc14 Proteins and the C Terminus of p53 Are Responsible for Their Interaction-To further confirm that the N terminus of hCdc14 interacts with p53, we performed binding assays using full-length recombinant GST-p53 proteins and various truncation mutants of hCdc14A and -B that had been synthesized by an in vitro translation procedure. Both hCdc14A 1-158 and hCdc14B 1-230 bound to GST-p53, whereas neither hCdc14A 120 -580 nor hCdc14B 150 -459 did (Fig.  2, A and B). As a control, we demonstrated that neither of these in vitro translated hCdc14 proteins interacted with the GST protein (data not shown).
We next performed in vitro binding assays to determine what domain of the p53 protein is involved in the interaction. 35 S-Labeled hCdc14A and hCdc14B proteins, synthesized from pET-Cdc14A or pET-Cdc14B by in vitro translation, were incubated with recombinant proteins of GST fused to various domains of the p53 protein as indicated in Fig. 2C. As shown in Fig. 2, D and E, the full-length GST-p53 protein as well as the GST-p53 250 -393 bound well to hCdc14A and hCdc14B, retaining ϳ20% of the input radiolabeled hCdc14s. In contrast, except for the p53 N terminus (GST-p53 1-210 ), which bound less than 2% of the input hCdc14B, GST-p53 1-210 , GST-p53 100 -296 , or GST could not bind tightly with hCdc14A or hCdc14B. Taken together, these results show that the N terminus of Cdc14 and the C terminus of p53 are required for the interaction.
It has been shown that the C terminus of p53 undergoes phosphorylation at multiple sites (reviewed in Ref. 13). p34 Cdc2 / clb kinase can specifically phosphorylate p53 Ser 315 in vitro as well as in vivo (10,14) whereas casein kinase II can specifically phosphorylate Ser 392 of human p53 (15,16). To examine whether the phosphorylation status of p53 can interfere with its binding with hCdc14, GST-p53 proteins were specifically labeled on Ser 315 or Ser 392 using P34 Cdc2 /clb kinase or CKII kinase, respectively. We found that GST-p53 with the Ser 315 to Ala mutation abolished the radioactive labeling by p34 Cdc2 /clb, suggesting the specific labeling of the Ser 315 site by p34 Cdc2 /clb (data not shown). Ser 315 -or Ser 392 -phosphorylated GST-p53 proteins bound equally well as unphosphorylated GST-p53 to the in vitro translated hCdc14A or hCdc14B protein (data not shown).
Human Cdc14 Protein Can Specifically Dephosphorylate Ser 315 of p53-hCdc14 has been shown to act as a dual specificity protein phosphatase (1). Because hCdc14A and hCdc14B were found to physically interact with the C terminus of p53, we next examined whether hCdc14 proteins dephosphorylate the C-terminal phosphorylation site(s) of p53. Recombinant hCdc14A and hCdc14B with C-terminal His 6 tag were purified from E. coli and incubated with GST-p53 phosphorylated at either Ser 315 or Ser 392 . Both hCdc14A and hCdc14B were able to dephosphorylate p53 phosphorylated at Ser 315 . About 30 -50% of the total label incorporated at Ser 315 was removed by hCdc14A or hCdc14B within 30 min of incubation (Fig. 3). In contrast, neither hCdc14A nor hCdc14B had any phosphatase activity toward p53 phosphorylated at Ser 392 (Fig. 3). As expected, the inactive mutant (hCdc14BCS) protein with its catalytic cysteine mutated to serine does not show any phosphatase activity against either site of p53. Two other unrelated phosphatases (PTEN and YG4E proteins) were used in the assay as controls. Like hCdc14, PTEN is a putative dual specific protein phosphatase with low activity against the artificial substrates p-nitrophenyl phosphate and 3-O-methylfluorescein phosphate (1). YG4E is an active protein phosphatase that exhibits strong activity against the substrates p-nitrophenyl phosphate and 3-O-methylfluorescein phosphate (data not shown). We found that neither PTEN nor YG4E could dephosphorylate GST-p53 phosphorylated at Ser 315 or Ser 392 (Fig. 3). DISCUSSION The yeast Cdc14 protein phosphatase plays important roles in the regulation of the cell cycle. As shown in the Fig. 4A, the yeast Cdc14 dephosphorylates several Cdc28/Clb substrates such as Hct1, Sic1, and Swi5. Cdc14-mediated dephosphorylation of Hct1 results in degradation of cyclin B (17), whereas dephosphorylation of the Cdc28/clb kinase inhibitor Sic1 results in Cdc28/clb accumulation (18). Cdc14-mediated dephosphorylation of the transcription factor Swi5 allows its nuclear translocation and subsequent transactivation of Sic1 (19). Taken together, the yeast Cdc14 appears to reverse the effects of Cdc28/clb by directly dephosphorylating proteins phosphorylated by Cdc28/clb (4, 17).
We recently cloned the human Cdc14 orthologs, hCDC4A FIG. 2. The N terminus of hCdc14 proteins and the C terminus of p53 are responsible for the interaction. A and B, 5 l each of the in vitro translated and 35 S-labeled hCdc14A, hCdc14A 1-158 , hCdc14A 120 -580 (A) or hCdc14B, hCdc14B 1-230 , hCdc14B 150 -459 (B) proteins were incubated with 50 l (ϳ300 ng) of agarose bead-immobilized GST-p53 fusion protein as described under "Materials and Methods." After washing, proteins stably bound to the agarose beads were separated by SDS-PAGE, dried, and exposed to x-ray film. Input, 1 l of the 50-l in vitro translation reaction. C, SDS-PAGE of purified GST-p53 fusion proteins. D and E, 5 l each of the in vitro translated and 35 S-labeled hCdc14A (D) or B (E) proteins were incubated with 50 l ( ϳ 300 ng) of agarose bead-immobilized GST or GST-p53 fusion proteins as described under "Materials and Methods." After washing, proteins stably bound to the agarose beads were separated by SDS-PAGE, dried, and exposed to x-ray film. Input, 1 l of the 50-l in vitro translation reaction. The ratio of free 32 P over total radioactivity was obtained. and hCdc14B (1). In this study, we found that hCdc14A and hCdc14B physically interact with the human tumor suppressor protein p53 both in vitro and in vivo. Such interaction specifically involves the highly conserved N termini of the hCdc14 proteins and the C terminus of the p53 protein. Furthermore, we showed that recombinant hCdc14A and hCdc14B specifically dephosphorylate p53 at Ser 315 , a site that has been shown to be phosphorylated by p34 Cdc2 /clb (10). No hCdc14 phosphatase activity was detected against p53 phosphorylated at the Ser 392 site, which can be phosphorylated by casein kinase II (13). Other phosphatases tested, such as PTEN or YG4E, show no in vitro activity toward p53 phosphorylated at either Ser 315 or Ser 392 . Our results that hCdc14s specifically dephosphorylate the p34 Cdc2 /clb phosphorylation site of p53 suggest that hCdc14 phosphatases may function analogously to the yeast Cdc14 by dephosphorylating substrate(s) of p34 Cdc2 /clb kinase.
p53 is a well studied tumor suppressor protein that plays important roles in the cellular response to DNA-damaging agents and other cellular stresses. p53 is normally present in low amounts in normal cells but accumulates in the cell nucleus in response to various cellular stresses (13). The nuclear accumulation of p53 leads to the transactivation of cyclin-dependent kinase inhibitor p21 WAF1 , causing cell cycle arrest at G 1 /S as well at the G 2 /M phase (20). In addition to their roles in G 1 cell cycle arrest, p53 and p21 WAF1 has been suggested to be involved in the regulation of the mitotic exit check point in mammalian cells (21). Loss or inactivation of p53 or p21 WAF1 is associated with tetraploidy or aneuploidy due to the failure of cytokinesis (22)(23)(24). Furthermore, p53 appears to stimulate the exit of mitosis following a transient G 2 /M cell cycle arrest induced by various DNA-damaging agents in many cell types (25). Considering the fact that yeast Cdc14 facilitates mitotic exit by dephosphorylating Cdc28/clb substrates and in turn deactivating Cdc28/clb activity, we speculate that hCdc14-dependent dephosphorylation of p53 (and other p34 Cdc2 substrates) may stimulate exit from mitosis in mammalian cells (Fig. 4B).
Human p53 has been shown to undergo numerous phosphorylations in vivo and in vitro. The phosphorylation status of p53 is determined by several kinases that target at least six different serines clustered in two domains on the protein (13). Two phosphorylated serines within the C terminus domain, Ser 315 and Ser 392 , are phosphorylated by p34 Cdc2 /clb and casein kinase II, respectively (10,15). p53 phosphorylation at Ser 392 can enhance p53 sequence-specific DNA binding in vitro and is important for p53-mediated transcriptional activation in vivo (26). In addition, UV irradiation has been reported to increase the Ser 392 phosphorylation (27,28). Prolonged stability and/or activation of p53 by those phosphorylation events under stress conditions lead to G 1 /S or G 2 /M arrest. Several phosphatases including PP2A and PP5 have been inferred to inhibit p53 transcriptional activity by regulating the phosphorylation status of p53, although the targeting sites of these phosphatases are not known (29,30). So far, the effect of Ser 315 phosphoryl-ation is not clear. Earlier studies showed that Ser 315 phosphorylation increases the sequence-specific DNA binding capacity of p53, suggesting that Ser 315 phosphorylation is an activating modification (10). However, mutation of the Ser 315 residue has been reported to prolong the half-life of the p53 protein, suggesting that phosphorylation of Ser 315 may target p53 for degradation (31). Contrary to those reports, recent studies in which Ser 315 and other phosphorylation sites had been mutated suggest no role for the Ser 315 in regulating the stability or activity of p53 (32,33). Because the Ser 315 site of p53 is located adjacent to its nuclear localization signal, it is conceivable that Ser 315 phosphorylation may regulate p53 localization. Experiments studying the p53 localization showed that mutating Ser 315 into alanine, which mimics constitutively dephosphorylated serine, does not affect the ability of p53 to translocate into the nucleus (34). However, it cannot be excluded from that study that phosphorylation of Ser 315 may result in cytoplasmic retention of p53. In fact, the regulation of p53 nuclear export has been shown to be an important mechanism by which cells regulate p53 stability (35)(36)(37). Because the previous studies addressing p53 Ser 315 phosphorylation were done using transient overexpression of p53 in transformed cell lines, they may fail to detect the effect of p53 Ser 315 phosphorylation in normal cells, where only a minute amount of p53 is present. Further studies are needed to clarify the function of p53 Ser 315 phosphorylation and its regulation by hCdc14 phosphatases.
In summary, our results demonstrate that hCdc14 proteins can interact with p53 and specifically dephosphorylate the p34 Cdc2 /clb-mediated Ser 315 phosphorylation in vitro. Such findings suggest that Cdc14 may be an evolutionary conserved cyclin-dependent kinase phosphatase. Because the yeast Cdc14 phosphatase dephosphorylates multiple Cdc28/clb substrates (3,4), it is possible that one or both of the human Cdc14 proteins can dephosphorylate multiple substrates phosphorylated by Cdks in mammalian cells. The fact that there are several closely related human p53 homologues recently being discovered (p73 and p63 ket ) raises an intriguing possibility that different hCdc14 proteins might regulate different p53 homologues. Further study regarding the regulation of hCdc14s will provide valuable insight toward the understanding of mammalian cell cycle control and the regulation of p53.